We could not find any results for:
Make sure your spelling is correct or try broadening your search.
- Analysis showed improvement in muscle morphology and increased levels of regeneration in muscle groups, including the diaphragm, quadriceps, and calf - No adverse events and no significant...
- The first healthy volunteer has been dosed in the first component of the Phase 1 study - Initial safety and pharmacokinetic data expected in Q4 2024 - Initiation of the second component of...
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle...
Dosing of first participant in a Phase 1 clinical trial of SAT-3247 anticipated in Q3 2024 Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech...
- Updated data in a canine model of Duchenne muscular dystrophy (DMD) show further increased improvement in muscle force over baseline of 195% at four-month point - Receipt of Orphan Drug and...
– SAT-3247 is a proprietary, oral small molecule drug being developed by Satellos as a novel treatment to regenerate skeletal muscle which is lost in Duchenne muscular dystrophy (DMD) – DMD is a...
– Investigational New Drug (IND) enabling preclinical and toxicology studies successfully completed – Initiation of a Phase 1 clinical trial of SAT-3247 anticipated in Q3 2024 Satellos Bioscience...
–SAT-3247 treatment improved muscle repair and regeneration in canine model of DMD – SAT-3247 treatment also improved muscle force in this canine model of DMD – Satellos remains on track to...
– Frank Gleeson, Satellos CEO, to participate in a panel discussion titled "Research Row: PPMD Moving the Needle" on June 29, 2024 – Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX:...
Satellos expects to begin first-in-human clinical trials mid-year for SAT-3247, an oral small molecule drug candidate in development as a novel regenerative medicine approach to treating DMD...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.06 | 10.3448275862 | 0.58 | 0.7 | 0.57 | 370624 | 0.60083637 | CS |
4 | 0.15 | 30.612244898 | 0.49 | 0.7 | 0.45 | 123082 | 0.5641644 | CS |
12 | 0.13 | 25.4901960784 | 0.51 | 0.7 | 0.45 | 78555 | 0.53364825 | CS |
26 | 0.13 | 25.4901960784 | 0.51 | 0.7 | 0.38 | 65111 | 0.52075497 | CS |
52 | 0.02 | 3.22580645161 | 0.62 | 0.8 | 0.38 | 69002 | 0.53977307 | CS |
156 | 0.02 | 3.22580645161 | 0.62 | 0.8 | 0.38 | 69002 | 0.53977307 | CS |
260 | 0.02 | 3.22580645161 | 0.62 | 0.8 | 0.38 | 69002 | 0.53977307 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions